Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

relative survival; young women; cancer treatment; n/a; fulvestrant; lapatinib; tumor biology; antihormone therapy; mastectomy; aromatase inhibitors; chemotherapy; serum biomarker; cyclin E; anthracycline resistance; zero-inflated Poisson regression model; lymph-node ratio; CHEK2; comparative effectiveness; breast-conserving therapy; taxane sensitivity; liquid biopsy; HER2 c-erbB2; colorectal cancer; infiltrating breast cancer; survival; exercise characteristics; lactate dehydrogenase; biomarker; breast cancer survivors; BRCA; disease-free survival; PIK3CA; metastatic breast cancer; cell-free DNA; invasive breast cancer; radiotherapy; Metformin; social well-being; gene expression; contralateral breast cancer; basal-like breast cancer; LMK-235; Src kinase; HER2/neu; LKB1; Older women; LDH; mutation carriers; stage IV; mammography screening; NCDB; cMet; SEER; pertuzumab; physical function; outcome; ribociclib; older patients; geriatric oncology; metastatic; overdiagnosis; next-generation sequencing; abemaciclib; Endocrine therapy; monitoring metastatic breast cancer; breast cancer; circulating tumor cells; Breast Cancer; PALB2; histone deacetylase; prognosis; physical activity; trastuzumab; ductal carcinoma in situ; contralateral prophylactic mastectomy; ERCC1; family history; T-DM1; ATM; advanced breast cancer; incidence; palbociclib; HDAC5 inhibitors; APOBEC3B